SBIR/STTR Research Award
Clinical Translation of an Anti-Metastatic Antibody for Breast Cancer Therapy
Award amount
$195,660Program and phase
SBIR · Phase IAward year
2013Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- OMADA HEALTH, INC.
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- YG51KXMC93B5
- Solicitation number
- PA12-088
- Topic code
- NIDDK
Research abstract
DESCRIPTION (provided by applicant): Approximately 32% of Medicare spending is attributed to diabetic populations, and the prevalence of diabetes is growing at an alarming rate. Approximately 79 million Americans have prediabetes. The landmark 2002 Diabetes Prevention Program (DPP) demonstrated that lifestyle modification is a successful approach to preventing diabetes. The DPP lifestyle changes reduced the risk of developing diabetes in patients with prediabetes by 58% at 3 years following the intervention. The DPP involved a curriculum of 16 lessons delivered one-on-one over 6 months and a follow-up maintenance program over the remaining year. While the DPP lifestyle modification program was overwhelmingly successful, its wide-spread implementation necessitates the development of cost-effective delivery channels. While the NIH and UnitedHealth Group have invested in a pilot program to adapt the curriculum to a group format delivered at the YMCA, alternatives that are scalable and accessible are necessary tomake the DPP available across a broader segment of society. Omada Health is developing an interactive DPP curriculum from the recently released CDC DPP curriculum; this curriculum is designed to be delivered on a user-friendly web-based platform that Omada Health has built for virtual small groups. The goal of this proposal is to enhance the basic DPP curriculum with interactive and tailored components to motivate and engage users, increase participation, and improve health outcomes. Research into specificelements of online behavior interventions has demonstrated that interactive features, such as personalized email contact and bulletin board participation, may improve user outcomes. Upon completion of these specific aims, Omada Health will conduct large pilot studies and commercialize the web-based DPP curriculum and platform through strategic partnerships. Omada Health's online distribution model makes this diabetes prevention program ideal for rapid, nationwide expansion. Not only is this solution scalable, but it is more convenient and accessible for individuals with limited time and does not depend on access to a particular geographic location or vendor. Thus, Omada Health's interactive DPP is an ideal alternative to the pioneering YMCA-based DPP and has the potential to revolutionize the delivery of diabetes prevention programs. Omada Health has assembled an impressive team of collaborators to support and enhance their efforts, including: Martha Funnell, MS, a prominent diabetes educatory and past-chairof the National Diabetes Education Program; Anne Peters, MD, a renowned dialectologist and head of the USC Clinical Diabetes Program; Mark Berman, MD, an internal medicine physician with a focus on lifestyle medicine; Chip Heath, PhD, Professor of Organizational Behavior at Stanford University, an expert in behavior modification; and Willem Van Lancker, a Lead User Experience Designer at Google. PUBLIC HEALTH RELEVANCE PUBLIC HEALTH RELEVANCE: Preventing diabetes in the estimated 79 million Americans with prediabetes is a public health priority. Lifestyle modification programs that focus on physica activity and healthy diet have been shown to be highly effective in preventing diabetes. The goal of this project is to develop interactive componentssuch as games, group response fields, quizzes, and videos to improve an online, virtual group diabetes prevention program to motivate users towards better health and to prevent diabetes.
Technology keywords
Not reported
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- ND Enabling Studies for CMT-101, a Novel Gene Therapy for Glycogen Storage Disease 1b
- Wearable Metabolic Sensor for Monitoring of Lactate and Glucose for People with Diabetes
- Novel Over-the-Scope Platform for Control of Variceal Bleeding
- Tolerogenic Nanotherapy to Delay Type I Diabetes
- An intravascular Bioartificial Pancreas (iBAP)